Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 14, 2020

SELL
$127.44 - $232.72 $873,473 - $1.6 Million
-6,854 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$108.83 - $165.23 $11,100 - $16,853
-102 Reduced 1.47%
6,854 $903,000
Q4 2019

Feb 14, 2020

BUY
$106.59 - $164.21 $37,199 - $57,309
349 Added 5.28%
6,956 $1.12 Million
Q3 2019

Nov 13, 2019

SELL
$113.31 - $150.51 $2.47 Million - $3.28 Million
-21,800 Reduced 76.74%
6,607 $753,000
Q2 2019

Aug 14, 2019

BUY
$115.0 - $141.58 $3.27 Million - $4.02 Million
28,407 New
28,407 $4.02 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $30.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track University Of Notre Dame Du Lac Portfolio

Follow University Of Notre Dame Du Lac and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of University Of Notre Dame Du Lac, based on Form 13F filings with the SEC.

News

Stay updated on University Of Notre Dame Du Lac with notifications on news.